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The Polo-like kinase (PLK) family comprises three serine/threonine kinases, functionally involved in signal transduction pathways
essential for the accomplishment of mitosis in both normal and malignant cells. Moreover, certain PLKs have been functionally linked
to cytoskeletal reorganisation. In this study, the expression of PLK1 and PLK3 was determined immunohistochemically in tissue
specimen of normal ovaries (n¼9), cystadenomas (n¼17), borderline tumours (n¼13) and ovarian carcinomas (n¼77). PLK 1 and
PLK3 expression was low in normal ovarian surface epithelium and borderline tumours, with moderately higher expression levels in
cystadenomas. In ovarian carcinomas, 26% of cases were PLK1 positive and 50.6% of cases were PLK3 positive. A positive correlation
of both PLK1 and PLK3 expression with indicators of mitotic frequency could be established. The overexpression of either isoenzyme
had an impact on patient prognosis with shortened survival time for patients with tumours positive for PLK1 (P¼0.02) and PLK3
(P¼0.02), but only PLK1 expression remained a prognostic factor in multivariate survival analysis (P¼0.03). The results of this study,
if interpreted in the context of recently published functional data, suggest that inhibition of PLKs might represent an interesting new
targeted approach for chemotherapy of epithelial ovarian cancer. Furthermore, this study suggests that PLK1 is a novel independent
prognostic marker in ovarian carcinomas.
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In most industrialised countries, ovarian cancer is the fifth leading
cause of cancer death in women with an overall of 14300 estimated
ovarian cancer-related deaths in the US in 2003 (Jemal et al, 2003).
More than 90% of ovarian malignancies arise from the ovarian
surface epithelium forming the group of epithelial ovarian
carcinoma.
Surgery and chemotherapy play a major role in the treatment of
ovarian carcinoma, but mortality has changed little over the past
20 years (Edmondson and Monaghan, 2001), indicating that the
biology of this tumour entity is still poorly understood. Owing to
the fact that ovarian cancer is usually detected at advanced disease
stages, chemotherapy is particularly important in these tumours.
Most drugs used in ovarian carcinoma treatment are effective in
mitotically active cells. Therefore, knowledge on regulation of
mitosis is an important step in establishing new treatment
strategies for these common tumours.
There is abundant evidence that Polo-like kinase (PLK) isoforms
play an important role in a number of intracellular signal
transduction pathways related to mitosis (see, for review, Nigg,
1998; Donaldson et al, 2001). The expression of members of this
kinase family in malignancies is of special interest, because
inhibitory strategies for PLKs might hinder tumour cells to
accomplish mitosis and subsequently induce tumour cell death
and reduce overall tumour growth.
The name of the PLK family stems from Drosophila gene Polo,
where this special type of serine/threonine kinases have first been
identified (Sunkel and Glover, 1988). In recent years, varying
numbers of Polo homologues have been discovered in a broad
variety of organisms, including yeast, certain bacteria, mice and
men. The family of human PLK isoenzymes, comprises to date
three family members, which are now named PLK1, PLK2 and
PLK3 (formerly designated as PLK, SNK and FNK), respectively
(Nigg, 1998). Sak, another kinase related to the PLK family
comprises only one Polo box, yet has been recently referred to as
PLK4 (Manning et al, 2002). All isoenzymes share a closely related
catalytic domain near the amino-terminal end of the protein and a
highly characteristic sequence motif, the so-called Polo boxes
near the carboxy-terminal end of the proteins. For PLK1, there
is convincing evidence that protein expression and kinase
activity peak through G2/M transition and that regular protein
function is necessary for the entry into and progression through
mitosis by a variety of different functional mechanisms (Donald-
son et al, 2001).
Studies on the expression of PLK1 have been performed on
carcinomas of lung (Wolf et al, 1997), head and neck (Knecht et al,
1999), oesophagus and stomach (Tokumitsu et al, 1999), skin
(Kneisel et al, 2002), breast (Wolf et al, 2000), brain (Dietzmann
et al, 2001), endometrium and ovary (Takai et al, 2001a,b). All
studies consistently reported an overexpression of PLK1 in the
respective tumour tissue compared to the corresponding non-
transformed tissue of origin. In addition, some studies suggested a
prognostic role for PLK1 expression.
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yIn contrast to the extensively studied PLK1 isoform, information
with respect to the expression, regulation and function of PLK3 is
sparse and results are somewhat contradictory. To our knowledge,
there are currently no studies available on the expression of PLK
isoform proteins other than PLK1 in either normal human tissue
or malignant human tumours.
Therefore, the aim of this study was to investigate the expression
of PLK1 and PLK3 in epithelial ovarian tumours and to perform an
in-depth exploration of the association between PLK isoform
expression, clinicopathological data and patient survival.
MATERIAL AND METHODS
Patients and tissue samples
Tissue samples were collected from 116 patients (age range: 28–85
years, median 59.5 years) who underwent surgery for diagnostic or
therapeutic purpose at the Charite ´ Hospital, Humboldt University,
Berlin between 1990 and 2001. The total of 116 samples was
subdivided in either normal ovaries (n¼9), removed for other
causes than malignant tumour, benign cystadenomas (n¼17),
borderline tumours (n¼13) or primary ovarian carcinomas
(n¼77).
None of the patients with malignant tumour received neoadju-
vant chemotherapy. Data on postsurgical chemotherapy were
available for 50 out of 77 patients with primary carcinomas, of
whom 41 (82%) received a platinum-based first-line chemother-
apy. The remainder received either no chemotherapy at all (six
cases, 12%) or other types of chemotherapy (three cases, 6%).
According to histology, the group of cystadenomas was further
subdivided into either serous type (n¼11) or mucinous type
(n¼6). The subgroup of borderline tumours was classified as
either serous (n¼10), mucinous (n¼2) or transitional cell (n¼1)
type. The group of malignant tissue comprises all major tumour
types of ovarian carcinoma, in detail 41 serous carcinomas, 13
undifferentiated carcinomas, 10 endometrioid carcinomas, six
mucinous carcinomas, four clear-cell carcinomas and three
transitional cell carcinomas were investigated. Diagnosis, tumour
type and histopathological tumour grading (according to the
Silverberg grading system of epithelial ovarian tumours) of each
sample was confirmed on standard H&E sections by one of the
authors (SH). Correlation analysis of PLK1/PLK3 staining with
clinicopathological data and patient prognosis was performed,
including only data of patients with primary ovarian carcinomas.
Immunohistochemistry
For immunohistochemical detection of PLK isoenzymes, mono-
clonal mouse antibodies against PLK1 (BD Transduction labora-
tories, San Diego, CA, USA.) and PLK3 (BD Transduction
laboratories) were used on 5mm thick paraffin sections. For both
antibodies specificity has been tested in preceding studies (Bahassi
el et al, 2002; Wang et al, 2002). For antigen retrieval, slides were
placed in 0.01 M sodium citrate buffer, pH 6.0 and boiled for 10min
in a pressure cooker. After several rinses in phosphate-buffered
saline (PBS) and pretreatment with blocking medium (DAKO,
Glostrup, Denmark) for 10min, slides were incubated with
primary antibody diluted 1:500 (PLK1/PLK3) in PBS for 1h at
room temperature and then at 41C overnight. After washing slides
in PBS, bound antibody was detected by a streptavidin–biotin
system according to a standard protocol with standard antibody
dilutions as provided by the manufacturer (BioGenex, San Ramon,
CA, USA). For colour development, a fast red system (Sigma,
Deisenhofen, Germany) was applied. After colour development
was stopped, slides were cover slipped using PBS/glycerol.
For evaluation of the proliferation index, the expression of KI-67
was assessed on tissue samples by using a monoclonal mouse
antibody (DAKO) directed against human KI-67 protein on 5mm
thick paraffin sections. To improve antigen retrieval, the slides
were cooked for 10min as described above. Slides were incubated
with primary antibody diluted 1:1000 in PBS with 5% BSA for 1h
at room temperature. Bound antibody was detected by using an
LSAB-Kit (DAKO) with standard protocol as supplied by the
manufacturer. Slides were viewed in a Leica DMRB microscope.
Evaluation of immunohistochemical tissue staining
Staining of all slides was evaluated independently by two
pathologists (WW and CD), who were blinded towards patient
characteristics and outcome. For semiquantitative evaluation, an
immunoreactivity-scoring (IRS) system was applied. Intensity of
staining was designated as either not existent (0), weak (1),
moderate (2) or strong (3). The number of cells stained was scored
as either no cells stained (0), less than 10% of cells stained (1), 10–
50% of cells stained (2), 50–80% of cells stained (3) or more than
80% of cells stained (4). The IRS was calculated by multiplication
of these two variables. For statistical analysis, cases were grouped
as either PLK negative (IRS 0–6) or PLK positive (IRS 7–12).
Statistical analysis
Statistical correlation between several clinicopathological factors
and expression of PLK was assessed using either w
2 test for trends,
Fisher’s exact test or Spearman’s test for rank-order correlation.
The probability of differences in overall survival as a function of
time was determined using a Kaplan–Meier analysis, with probing
of significance by applying a log-rank test. Multivariate probing
for significance was performed with the Cox’s proportional-hazard
model. Generally, P-values smaller than 0.05 were considered
significant. For all statistical procedures SPSS v10.0 software was
used.
RESULTS
Expression of PLK isoforms in ovarian tissue
The expression of PLK1 was determined in nontransformed
ovarian tissue and could not be observed in any normal ovarian
surface epithelium investigated, nor did ovarian stroma show
PLK1 positivity. Inclusion cysts of ovarian surface epithelium were
consistently PLK1 negative. Follicular cysts, present in some but
not all ovaries, showed strong staining for PLK1 in theca externa
cell layer and served as internal positive control. Corpora lutea
showed focal PLK1 positivity.
In cystadenomas, considerable expression of PLK1 was observed
in three out of 17 cases (17.6%). Expression was pronounced
in papillary areas. Despite weak focal positivity in the majority
of borderline tumours, they were all scored negative. In contrast,
20 out of 77 primary ovarian carcinomas (26%) displayed
strong cytoplasmic PLK1 expression (Table 1, Figure 1). Never-
theless, minor cytoplasmatic staining in a subpopulation of
tumour cells could be observed in the epithelium of all tumours.
In those cases in which notable PLK1 expression was present and
in which infiltrative tumour margins could be seen, PLK1
expression was accentuated on the leading edge of tumour
invasion.
PLK3 expression was not detectable in the epithelium of eight
(88.9%) out of nine normal ovaries investigated. In one case,
immunoreactivity for PLK3 was detected in infoldings of the
ovarian surface epithelium but was negative for the surface
epithelium. A minor fraction of inclusion cysts (approximately
10%), present in normal ovaries, showed notable focal expression
of PLK3. Theca externa of follicular cysts as well as corpora lutea
expressed PLK3 strongly and homogeneously.
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17 cases (29.4%). Expression was pronounced in papillary tumour
areas. In borderline tumours, there was considerable PLK3
positivity in two out of 13 cases (13.4%), although all cases showed
scattered focal PLK3-positive cells. In the group of primary
ovarian carcinomas, 39 out of 77 cases (50.6%) were PLK3
positive (Table 1, Figure 1), usually with pronounced PLK3
expression along the infiltrative tumour margins. As mentioned
for PLK1, nearly all PLK3-negative tumours expressed inhomo-
geneously small, albeit detectable amounts of cytoplasmatic PLK3
protein. In the stroma of normal ovaries as well as in tumour
stroma single inflammatory cells showing strong PLK3 expression
were occasionally observed.
Correlation of PLK1/PLK3 expression with
clinicopathological factors
For PLK1 and PLK3 expression, statistical correlation analysis with
several clinicopathological factors was performed including all
cases of primary ovarian carcinoma (n¼77).
Ungrouped PLK1 as well as PLK3 expression scores were found
to correlate with moderate strength to mitotic figure count
(Figure 2). Correlation coefficient as determined by Spearman’s
test for rank-order correlation reached 0.229 for PLK1 (P¼0.044)
and 0.254 for PLK3 (P¼0.026), respectively. In a subgroup of
ovarian carcinomas (n¼54) in which data on KI-67 expression
were available, a significant positive correlation of PLK1/PLK3-
positive tumours towards higher KI-67 indices in comparison to
PLK1/PLK3-negative tumours was observed (Figure 2). P-values
for these correlations, calculated by the w
2 test for trends, reached
0.027 for PLK1 and 0.019 for PLK3, respectively.
Usually, the percentage of PLK1/PLK3-positive cells was higher
than the KI-67-positive proliferation fraction, so that there was no
strict coexpression.
No correlation was observed between PLK1 (P¼0.165)
and PLK3 (P¼0.289) expression and FIGO stage (Tables 2 and
3). There was a significant positive correlation for PLK3
(P¼0.025) but not for PLK1 (P¼0.125) expression with
histopathological tumour grade, high-grade tumours being sig-
nificantly more likely to express PLK3 than low-grade tumours
(Tables 2 and 3).
PLK1 expression as well as PLK3 expression had a significant
impact on patient prognosis in univariate survival analysis
(Figure 3). Median survival time for patients whose carcinomas
were PLK1 or PLK3 negative was not reached, while median
survival time for patients with PLK1- and PLK3-positive
carcinomas in either groups was 37.9 month (log-rank test for
PLK1: P¼0.022; log-rank test for PLK3: P¼0.021). The median
survival rate after 24 month of follow-up was 52.9% for
PLK1-positive cases vs 70.2% for PLK1-negative cases and 59.4%
for PLK3-positive cases vs 72.7% of PLK3-negative cases,
respectively. Univariate survival analysis for other clinicopatholo-
gical tumour features, known to be prognostic factors in
ovarian carcinomas revealed a significant prognostic relevance
for patient’s age at diagnosis (Po0.01), FIGO stage (Po0.01)
and Silverberg grading (Po0.01), respectively (Table 4). In
multivariate survival analysis, under the inclusion of all
factors that had a significant impact on patient prognosis
in univariate survival analysis, PLK3 expression failed to
show independent prognostic significance (P¼0.49). In contrast,
PLK1 expression remained a significant prognostic factor in
multivariate survival analysis (Table 5) with a P-value of 0.03.
Patients whose tumours showed high PLK1 expression had a 2.4-
fold risk of dying (confidence interval: 1.1–5.4) in the given time
interval compared to patients with tumours expressing low
amounts of PLK1.
Table 1 Distribution of PLK1 and PLK3 expression in normal ovaries, cystadenomas, borderline tumours and primary ovarian carcinomas
Primary carcinomas
(n¼77)
Borderline tumours
(n¼13)
Benign cystadenomas
(n¼17)
Normal ovaries
(n¼9)
PLK1
Negative (IRS 0–6) 57 (74%) 13 (100%) 14 (82.4%) 9 (100%)
Positive (IRS 7–12) 20 (26%) 0 (0%) 3 (17.6%) 0 (0%)
PLK3
Negative (IRS 0–6) 38 (49.4%) 11 (84.6%) 12 (70.6%) 8 (88.9%)
Positive (IRS 7–12) 39 (50.6%) 2 (13.4%) 5 (29.4%) 1 (11.1%)
PLK¼Polo-like kinase; IRS¼immunoreactivity-scoring system.
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Figure 1 Expression of PLK1 and PLK3 in ovarian tissue specimen. (A)
Normal ovarian surface epithelium without significant PLK1 positivity (small
arrows) and moderate PLK1 positivity in an adjacent serous cystadenoma
(bold arrows). (B) Serous borderline tumour of the ovary showing only
weak scattered expression of PLK3. This tumour was scored as PLK3
negative. (C, D) Serous ovarian carcinoma with strong expression of PLK1
in more than 80% of tumour cells (C), while the same tumour showed only
low expression for PLK3 (D). (E, F) Undifferentiated ovarian carcinoma
staining strongly positive for PLK3 (F) but not for PLK1 (E).
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Since the first description of Drosophila gene Polo 15 years ago
(Sunkel and Glover, 1988), PLK isoenzymes have been the focus of
intense investigative efforts. While early works in this field
concentrated mainly on the identification of Polo homologues in
different species and on the role of this enzyme family in normal
tissue development and mitosis, the focus of interest has changed
towards the functional and prognostic role of PLK isoenzymes in
human malignancies.
The central role of PLK isoenzymes in tumorigenesis has been
emphasised lately by studies showing that PLK1 inhibition, either
by antisense or siRNA, leads to dramatic antiproliferative effects
on tumour cells in vitro (Spa ¨nkuch-Schmitt et al, 2002a,b; Elez
et al, 2003; Liu and Erikson, 2003), pointing at a potential
therapeutic use of inhibitory strategies targeting PLK isoenzymes.
In-depth expression analysis of members of the PLK family in
various cancers and correlation with other tumour characteristics
may thus provide the translational basis for such approaches in
clinical practice.
In earlier studies, we and others found PLK1 overexpressed in a
variety of tumours, compared to the respective corresponding
tissue of origin, suggesting an important role of high levels of PLK
isoenzymes for tumour growth. For PLK isoenzymes other than
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Figure 2 Polo-like kinase isoform expression and correlation to indicators of mitotic frequency. (A, B) Diagrams showing the distribution of PLK1
expression (A) and PLK3 expression (B) in dependence of mitotic figure count in the respective tumours. (C, D) Distribution of KI-67 index in a subgroup
of PLK1-positive/negative carcinomas (C) and PLK3-positive/negative carcinomas (D)( n¼54).
Table 2 Correlation of PLK1 expression with several clinicopathological factors
All cases PLK1 negative (IRS 0-6) PLK1 positive (IRS 7-12) P-value
Age
o60 years 42 (54.5%) 30 (71.4%) 12 (28.6%) 0.611
+
460 years 35 (45.5%) 27 (77.1%) 8 (22.9%)
FIGO stage
I 17 (22.1%) 15 (88.2%) 2 (11.8%)
II 9 (11.7%) 6 (66.7%) 3 (33.3%) 0.165*
III 46 (59.7%) 33 (71.7%) 13 (28.3%)
IV 5 (6.5%) 3 (60%) 2 (40%)
Grade
G1 15 (19.5%) 13 (86.7%) 2 (13.3%)
G2 33 (42.9%) 25 (75.8%) 8 (24.2%) 0.125*
G3 29 (37.6%) 19 (65.5%) 10 (34.5%)
+Fisher’s exact test; *w
2 test for trends. PLK¼Polo-like kinase; IRS¼immunoreactivity-scoring system.
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tumour entities is available, with only one study in mice report-
ing a relative loss of expression for PLK3 mRNA in colon
carcinomas in comparison to adjacent normal colon mucosa
(Dai et al, 2002).
In this study on epithelial ovarian tumours, we observed
that normal ovarian surface epithelium as well as ovarian stroma
does not express PLK1 or PLK3. The expression of PLK1 and
PLK3 was elevated in a fraction of cystadenomas and was
even higher in the group of primary ovarian carcinomas,
whereas borderline tumours tended to express lower levels of
PLK1 and PLK3 compared to other epithelial tumour entities of the
ovary.
This finding might be in line with the concept that serous
borderline tumours of the ovary should not be placed as an
‘intermediate lesion’ between benign cystadenomas and invasive
carcinomas (Dietel and Hauptmann, 2000), but should be regarded
as an independent tumour entity.
Table 3 Correlation of PLK3 expression with several clinicopathological factors
All cases PLK3 negative (IRS 0-6) PLK3 positive (IRS 7-12) P-value
Age
o60 years 42 (54.5%) 22 (52.4%) 20 (47.6%) 0.649
+
460 years 35 (45.5%) 16 (45.7%) 19 (54.3%)
FIGO stage
I 17 (22.1%) 9 (52.9%) 8(47.1%)
II 9 (11.7%) 5 (55.6%) 4 (44.4%) 0.289*
III 46 (59.7%) 24 (52.2%) 22 (47.8%)
IV 5 (6.5%) 0 (0%) 5 (100%)
Grade
G1 15 (19.5%) 12 (80%) 3 (20%)
G2 33 (42.9%) 14 (42.4%) 19 (57.6%) 0.025*
G3 29 (37.6%) 12 (41.4%) 17 (58.6%)
+Fisher’s exact test. *w
2 test for trends. PLK¼Polo-like kinase; IRS¼immunoreactivity-scoring system.
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Figure 3 Correlation between patient survival and expression of PLK1
or PLK3. Kaplan–Meier curves for patients grouped as either PLK1 positive
or PLK1 negative (A) and PLK3 positive or PLK3 negative (B). Respective
P-values in log-rank test for significant differences in survival time were
P¼0.022 for PLK1 and P¼0.021 for PLK3.
Table 4 Correlation of several clinicopathological factors and of PLK1/
PLK3 expression with patient survival (log-rank test)
Median survival
(month) Standard error
Log-rank test
(P-value)
Age at diagnosis
o60 years 75.90 20.58 0.0009
460 years 22.53 6.19
FIGO stage
I Not reached —
II 52.47 29.67 0.0001
III 41.23 7.52
IV 1.7 0.99
Grade
G1 Not reached — 0.0015
G2 41.23 7.96
G3 35.03 5.24
PLK1
Negative Not reached — 0.0222
Positive 37.90 13.91
PLK3
Negative Not reached — 0.0207
Positive 37.90 8.45
PLK¼Polo-like kinase; IRS¼immunoreactivity-scoring system.
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reported an overexpression of PLK1, which correlated positively
with tumour stage and tumour grade (Takai et al, 2001b). In our
expanded study population we were not able to reproduce these
correlations.
However, we have shown that PLK1 overexpression has
independent prognostic significance in ovarian carcinomas. This
hypothesis matches well with observations that PLK1 expression is
a survival parameter in oesophageal carcinoma (Tokumitsu et al,
1999), lung carcinoma (Wolf et al, 1997) and squamous cell
carcinoma of head and neck (Knecht et al, 1999), and serves as a
marker for metastatic disease in malignant melanoma (Kneisel
et al, 2002).
With respect to its function, there is convincing evidence that
PLK1 is essential in G2/M-phase transition of both normal and
malignant cells. This isoenzyme is able to activate CDC25c which
in turn activates the CDC2/Cyclin B1 complex leading to the
import of Cyclin B1 into the nucleus (Toyoshima-Morimoto et al,
2002). Moreover, a recent study suggests that PLK1 is able to
phosphorylate Cyclin B1 (Jackman et al, 2003) directly, and
that specific phosphorylation cooperated with other signals in
the nuclear import of Cyclin protein, a crucial checkpoint for
the initiation of mitosis (Yuan et al, 2002). Later in mitosis,
PLK1 has been implicated in the regulation of the anaphase-
promoting complex (Kotani et al, 1998; Golan et al, 2002),
centrosome maturation and destructions of cohesins (Sumara
et al, 2002).
Data for PLK3 function is sparse and somewhat contra-
dictory. Some authors suggested that PLK3 protein levels and
kinase activity peak in late S and G2 phase (Ouyang et al, 1997;
Chase et al, 1998), while other authors did not find any change
of PLK3 expression throughout the cell cycle (Bahassi el
et al, 2002).
The importance of PLK isoenzymes for mitosis in ovarian
carcinoma is underlined by our finding that the expression of both
PLK1 and PLK3 correlated with the mitotic activity. Nevertheless,
it is surprising that only part of the variability of PLK isoform
expression in our study population can be explained by variation
in the number of mitotic figures, which might in part be due to
technical difficulties in identifying mitotic cells in fixed tissue
specimen.
On the other hand, one possible explanation might be that apart
from the suggested role in mitosis, there might exist additional
functions of PLK isoforms in intracellular signal transduction
pathways. It has been reported that PLK3 is overexpressed in
adherent vs nonadherent macrophages, and that it interacts
with calcium- and integrin-binding protein (CIB), a small
protein involved in integrin signalling pathways (Holtrich et al,
2000). As PLK3 is also expressed in irreversible postmitotic
cells like neuronal ganglion cells (data not shown), it is intri-
guing to speculate on the basis of data obtained in neuronal
cells (Kauselmann et al, 1999) and in macrophages (Holtrich
et al, 2000) that the proposed interaction of PLK3 with CIB might
play a role in determining the adhesiveness of tumour cells,
albeit functional evidence for such a role of PLK3 in tumours
is lacking.
Nevertheless, an additional functional role of PLK isoforms in
determining adhesiveness and invasiveness of tumour cells might
match with our observation that PLK isoform expression is
pronounced at the leading edge of tumour invasion in ovarian
carcinoma, which confirmed part of the observations made by
Takai et al (2001b).
Taken together, we showed that PLK1 and PLK 3 are frequently
overexpressed in highly proliferating malignant epithelial ovarian
tumours and that overexpression is associated with mitosis and
worse patients prognosis. We additionally hypothesised that PLK1
expression might serve as an independent prognostic factor in
ovarian carcinomas. Further functional studies are needed to
enlighten the possible role of PLK isoforms in the progression of
these tumours and to answer the question as to whether the role
of PLK isoforms in either mitotic machinery or regulation of
other signal transduction pathways, determining malignant cell
behaviour, might define them as attractive targets for novel forms
of directed tumour therapy.
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